



Kansas Medical Assistance Program: Fee-For-Service Program Assessment State Fiscal Year 2020

Prepared by Health Information Designs, LLC
Christina Faulkner, PharmD, BCPS

October 2020

Utilization and Expenditures Overview

SFY 2016 - 2020

	SFY 2020	SFY 2019	SFY 2018	SFY 2017	SFY 2016
Total Expenditures	\$14,015,861	\$13,284,851	\$12,992,968	\$10,391,867	\$8,096,516
Total Claims	49,080	52,178	57,611	52,518	45,358
Total Members	19,558	20,002	34,505	19,098	33,464
Total Users	2,920	2,745	2,827	2,842	1,729
Cost Per Member	\$717	\$664	\$377	\$544	\$242
Cost Per User	\$4,800	\$4,840	\$4,596	\$3,657	\$4,682
Cost Per Claim	\$286	\$255	\$225	\$198	\$178

Table 1: FFS Program Summary for SFY 2020 Compared to SFY 2019, SFY 2018, SFY 2017, and SFY 2016

Utilization and Expenditures Overview SFY 2020




Figure 4: All FFS Users, Claims, and Expenditures per Month for SFY 2020

Share of FFS Claims SFY 2020




Figure 8: ADAPD, TXIX, and MKN Share of SFY 2020 FFS Claims

During SFY 2020, the TXIX program had 32,025 claims, which accounted for 65% of the 49,080 FFS claims paid. The MKN program accounted for 17%. The ADAPD program accounted for 17%. The remaining 1% of FFS claims come from other coverage plans in the FFS population.

Share of FFS Expenditures SFY 2020




Figure 9: ADAPD, TXIX, and MKN Share of SFY 2020 FFS Expenditures

While the ADAPD program only accounted for 17% of the claims paid for FFS, it accounted for 75% of total expenditures. During SFY 2020, over \$14 million was paid for FFS claims, with \$10.5 million going toward ADAPD claims. The TXIX program accounted for 65% of the FFS claims paid but only 21% of the expenditures during SFY 2020. The MKN program accounted for 17% of the FFS claims and 4% of the expenditures during SFY 2020. The remaining (<1%) of FFS expenditures come from other coverage plans in the FFS population and the expenditures were negligible.

Antiretroviral Utilization

Figure 14 shows claims and expenditures for antiretroviral agents for SFY 2020.




Figure 14: Claims and expenditures for antiretroviral agents in SFY 2020

The number of claims was 6,192 and 7,180 for SFY 16 and SFY 20, respectively, an increase of approximately 16%. The expenditures increased from \$5.3 million dollars to \$10.6 million dollars for SFY 16 and SFY 20. The expenditures almost doubled in that time, likely due to the release of new antiretroviral agents on the market.

Users on Concurrent Benzodiazepines and Opioids and Users on Concurrent Antipsychotics and Opioids Trend Summary




Figure 12: Users on combination therapy with benzodiazepines, opioids, and antipsychotics in SFY 2019




Figure 13: Users on combination therapy with benzodiazepines, opioids, and antipsychotics in SFY 2020